We show that one of them, an intrachromosomal deletion generating a fusion between BCAN and NTRK1, drives the formation of aggressive high-grade gliomas and confers sensitivity to entrectinib, an experimental pan-Trk kinase inhibitor currently in clinical testing in a multicentre basket study (NCT02568267). Here, NTRK1 is linked to glioma.